Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pathbiotek (PBTK) -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Fortune who wrote (119)	11/3/1998 11:28:00 AM
From: Howard C.	Respond to of 394

Here's a press release from Sept 28 which is one of the dumbest I have ever seen...a "medical breakthrough" which offers no backup, no proof, nothing. I will call World Vision one more time, and if I don't get a good answer (ie, references) I might consider naiing them with the SEC also. Monday September 28, 9:00 am Eastern Time Company Press Release SOURCE: Pathobiotek Diagnostics Inc. Pathobiotek Diagnostics Inc. Announces Medical Breakthrough HOUSTON, Sept. 28 /PRNewswire/ -- Pathobiotek Diagnostics Inc. (OTC Bulletin Board: PBTK - news) announced that the development of a molecular diagnostic kit for multiple sclerosis (MS) is approximately six months ahead of schedule. Luther E. Lindner, MD, Ph.D., CSO of PBTK stated, ''Pathobiotek is developing a molecular diagnostic kit to aid in the diagnosis of MS and monitor its activity. We do not know of any similar product that determines whether a patient is actively afflicted with multiple sclerosis.'' Pathobiotek researchers have isolated a bacterium that appears to be a causal cofactor of MS. Laboratory tests have shown that this bacterium correlates with symptoms of the disease. The diagnostic kit is considered to be a research tool and as such does not require FDA trials before marketing. The company is presently in negotiations with a major pharmaceutical company for licensing rights to the kit. Lindner says, ''We are very excited about making the kit available and feel that it will aid greatly in the diagnosis of this disease worldwide. We feel that the ability to definitively diagnose MS will help determine the effectiveness of treatment for the dreaded disease which afflicts 300,000 people in the U.S. alone.'' For further information contact WorldVision at 407-834-8944 or 888-345-6060. Check out the company's website at www.wvfg.com or e-mail the company at relations@wvfg.com.